MX2023009249A - Método para prevenir, tratar o mejorar la colitis ulcerosa. - Google Patents

Método para prevenir, tratar o mejorar la colitis ulcerosa.

Info

Publication number
MX2023009249A
MX2023009249A MX2023009249A MX2023009249A MX2023009249A MX 2023009249 A MX2023009249 A MX 2023009249A MX 2023009249 A MX2023009249 A MX 2023009249A MX 2023009249 A MX2023009249 A MX 2023009249A MX 2023009249 A MX2023009249 A MX 2023009249A
Authority
MX
Mexico
Prior art keywords
amiselimod
ulcerative colitis
treating
preventing
ameliorating
Prior art date
Application number
MX2023009249A
Other languages
English (en)
Spanish (es)
Inventor
Jimin Lee
Neal Slatkin
Ezra R Lowe
Zeev Heimanson
Original Assignee
Bausch Health Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch Health Ireland Ltd filed Critical Bausch Health Ireland Ltd
Publication of MX2023009249A publication Critical patent/MX2023009249A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Luminescent Compositions (AREA)
  • Cereal-Derived Products (AREA)
MX2023009249A 2021-02-08 2022-02-08 Método para prevenir, tratar o mejorar la colitis ulcerosa. MX2023009249A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163147060P 2021-02-08 2021-02-08
PCT/EP2022/053030 WO2022167690A1 (en) 2021-02-08 2022-02-08 Amiselimod for preventing, treating, or ameliorating ulcerative colitis

Publications (1)

Publication Number Publication Date
MX2023009249A true MX2023009249A (es) 2023-10-23

Family

ID=80447376

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009249A MX2023009249A (es) 2021-02-08 2022-02-08 Método para prevenir, tratar o mejorar la colitis ulcerosa.

Country Status (9)

Country Link
US (1) US20240299318A1 (cg-RX-API-DMAC7.html)
EP (1) EP4288041A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024506041A (cg-RX-API-DMAC7.html)
CN (1) CN116940350A (cg-RX-API-DMAC7.html)
AU (1) AU2022217475A1 (cg-RX-API-DMAC7.html)
CA (1) CA3207440A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023009249A (cg-RX-API-DMAC7.html)
TW (1) TW202245742A (cg-RX-API-DMAC7.html)
WO (1) WO2022167690A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025134072A1 (en) * 2023-12-21 2025-06-26 Bausch Health Ireland Limited Methods for preventing, treating, or ameliorating ulcerative colitis in certain patient populations with amiselimod

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
RU2433117C2 (ru) 2005-12-15 2011-11-10 Мицубиси Танабе Фарма Корпорейшн Аминное соединение и его применение в медицинских целях
MX367667B (es) 2008-12-22 2019-08-30 Novartis Ag Régimen de dosificación de un agonista de los receptores de s1p.
MA40775A (fr) * 2014-10-01 2017-08-08 Respivert Ltd Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38
CA3002540C (en) * 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
US20180228778A1 (en) * 2015-08-11 2018-08-16 Akaal Pharma Pty Ltd Compositions comprising s1p receptor modulators
WO2018237379A2 (en) * 2017-06-23 2018-12-27 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
TWI721483B (zh) * 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
CN113613640B (zh) * 2018-09-08 2024-11-29 谭文 肾上腺素能β2受体激动剂R-对映体在治疗炎症性肠病及其肠外疾病的新应用
US20220390464A1 (en) * 2019-07-30 2022-12-08 Children's Medical Center Corporation Methods and compositions for characterizing inflammatory bowel disease

Also Published As

Publication number Publication date
JP2024506041A (ja) 2024-02-08
TW202245742A (zh) 2022-12-01
EP4288041A1 (en) 2023-12-13
AU2022217475A1 (en) 2023-08-24
CN116940350A (zh) 2023-10-24
WO2022167690A1 (en) 2022-08-11
CA3207440A1 (en) 2022-08-11
US20240299318A1 (en) 2024-09-12

Similar Documents

Publication Publication Date Title
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
ZA202005388B (en) Methods of treating ulcerative colitis
PH12017500933A1 (en) Sublingual administration of riluzole
CR20200228A (es) COMPOSICIONES Y MÈTODOS PARA MODULAR LA EXPRESIÒN DEL FACTOR B DEL COMPLEMENTO (Divisional 2016-0554)
MX2021007076A (es) Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol.
MX2022003193A (es) Tratamiento de encefalopatia asociada al gen syngap1.
PH12017500934A1 (en) Sublingual formulation of riluzole
MX2018001435A (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
MX2017017171A (es) Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias.
JOP20180110A1 (ar) تركيبات وطرق لمعالجة أو الوقاية من اضطرابات متعلقة بأوكسالات
MX2023006744A (es) Compuestos antihelminticos que comprenden una estructura de tienopiridina.
MY197209A (en) Uses of benzimidazole derivative for nocturnal acid breakthrough
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
TW201613639A (en) Methods for treating cardiovascular diseases
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
MX2023001328A (es) Compuestos de tiofeno para su uso en el tratamiento de la fibrosis renal.
MX394182B (es) Proceso continuo para la preparacion de trazodona
MX2019004804A (es) Tratamiento para el prurigo nodula.
MX382608B (es) Tratamiento del prurito urémico.
GEAP202315302A (en) METHOD FOR TREATING TNFα-RELATED DISEASE
MX2023004881A (es) Inhibidores de pde9 para el tratamiento de insuficiencia cardíaca.
ZA202108094B (en) Mirikizumab for use in a method of treating crohn's disease
AU2017245414A1 (en) The cure for cancer